Akebia (AKBA) Q4 2025 earnings review
Vafseo Launch Hit by Inventory Shock, but Auryxia Saves the Year
Akebia's Q4 results presented a stark divergence: the highly anticipated Vafseo launch abruptly reversed trajectory, while legacy drug Auryxia delivered surprisingly robust cash flow. Vafseo net product revenue collapsed to $6.2M (down from $14.3M in Q3). This was not a complete demand failure, but rather a painful operational transition: underlying patient demand was ~$11M, but a $4.5-$5M channel inventory adjustment completely masked it as clinics shifted to a new 'observed dosing' protocol. Net loss expanded to $12.2M, driven primarily by a one-time $12.8M R&D charge for a newly acquired pipeline asset. Despite the messy quarter, the company ended 2025 with $184.8M in cash and a fortified balance sheet.
🐂 Bull Case
The painful Vafseo Q4 inventory adjustment was caused by US Renal Care (USRC) switching to a 3-times-weekly (TIW) in-center dosing protocol. This pivot worked: first-refill adherence jumped from 75% to 91% in Q4, establishing a much stickier revenue base for 2026.
Thanks to Auryxia's resilience, Akebia ended 2025 with $184.8M in cash (up from $51.9M a year ago). Management claims this provides at least two years of runway, de-risking the Vafseo launch timeline.
🐻 Bear Case
Even adjusting for the $4.5-$5M inventory drawdown, underlying Vafseo patient demand was only ~$11M in Q4, down from Q3. Providers delayed new patient starts while anticipating the rollout of the new dosing protocol.
Auryxia generated $181.5M in 2025, effectively funding the company. But with broader generic competition expected in 2026, this cash cow is officially guided to shrink, putting intense pressure on Vafseo to scale rapidly.
⚖️ Verdict: ⚪
Neutral. The Q4 Vafseo optics are terrible, but the underlying operational shift to in-center observed dosing is the right long-term move to fix adherence. Auryxia's massive outperformance in 2025 gave management the financial breathing room to execute this transition, though 2026 leaves no room for further launch missteps.
Key Themes
Vafseo Launch Hits a Protocol Speedbump
Vafseo net product revenue reversed sharply from $14.3M in Q3 to $6.2M in Q4. The core issue: USRC transitioned from daily home dosing to an in-center, 3-times-weekly observed dosing protocol. This required a shift from 150mg to 300mg tablets, forcing USRC to burn through existing channel inventory (a $4.5-$5.0M headwind). Furthermore, physicians delayed new patient starts in Q4 while waiting for the new protocols to go live. This highlights extreme sensitivity to operational friction at the clinic level.
The Protocol Pivot Fixes Adherence
While the transition to in-center observed dosing hurt Q4 revenue, it successfully solved Vafseo's biggest structural flaw: poor patient adherence. For centers that adopted the in-center protocol in Q4, first-refill adherence rates skyrocketed to 91%, up from 75% during the first 9 months of 2025. This sets a foundation for highly recurring, predictable revenue per patient moving forward.
Diversifying the Prescriber Base
Akebia is finally breaking its over-reliance on USRC. In Q4, roughly 25% of new patients originated from dialysis organizations other than USRC, a significant acceleration from less than 10% in Q3. Total prescribers also increased 10% sequentially to roughly 800. This indicates the broader, prescriber-driven growth strategy is starting to take root.
Auryxia's Defying Gravity, But the Fall is Coming
Auryxia continues to drastically overperform expectations, posting $48.1M in Q4 (up YoY from $44.4M). Despite losing exclusivity in March 2025, the lack of widespread generic competition has allowed it to generate $181.5M for the full year. However, management explicitly stated they expect generic competition to expand beyond the current authorized generic in 2026, meaning this critical cash flow stream will decelerate.
Pipeline Expansion into Rare Kidney Disease
Akebia is aggressively pivoting beyond anemia. In November 2025, the company acquired AKB-097, a tissue-targeted complement inhibitor from Q32 Bio. This drove a $12.8M one-time charge in Q4, heavily skewing the net loss, but sets the stage for a Phase 2 open-label basket study in IgA nephropathy, lupus nephritis, and C3 glomerulopathy in 2H 2026.
Building the Clinical Case for Standard of Care
Management continues to rely on clinical superiority to drive long-term adoption. At ASN Kidney Week, a post-hoc analysis from the INNO2VATE trials showed vadadustat had statistically significant favorable outcomes in a composite of all-cause mortality and hospitalization versus ESAs. This claim is currently being tested directly in the VOICE and VOCAL post-marketing trials, with data expected in late 2026 and early 2027.
Other KPIs
Accelerating sharply compared to $11.8M in 24Q4. However, the optics are misleading: $12.8M of this was a one-time acquired in-process R&D charge for the AKB-097 asset from Q32 Bio. The remainder of the increase was driven by clinical trials for Vafseo (VOICE, VOCAL) and the praliciguat Phase 2.
A massive improvement from $51.9M at the end of 2024, driven by a combination of public offerings earlier in the year and robust cash generation from Auryxia. This balance sheet strength completely removes near-term dilution risk, with management citing enough runway for at least two years.
Guidance
Accelerating. While management did not provide a specific hard number, they expect the combination of resolved adherence issues (observed dosing), expanded LDO access (DaVita rollout), and steady new patient starts to drive a major inflection from the $45.8M baseline established in 2025.
Decelerating. Management formally expects Auryxia revenues to fall below the $181.5M achieved in 2025 as generic competition expands. The steepness of this decline will dictate how quickly Vafseo needs to ramp to prevent a return to heavy operational cash burn.
Stable. The company expects existing cash of $184.8M and ongoing revenues to comfortably fund the current operating plan, which includes launching the rare kidney disease basket study and pushing AKB-9090 into Phase 1.
Key Questions
DaVita Dosing Protocols
With USRC's transition to 3-times-weekly observed dosing causing a severe short-term inventory and start-delay shock, are we expecting DaVita and other expanding LDOs to adopt this protocol from day one, or will we see similar operational turbulence as they transition later?
Auryxia Generic Erosion Curve
You've guided for Auryxia revenue to decrease in 2026 due to expanded generic competition. What are your specific assumptions regarding the timing of new ANDA approvals, and how steep do you model the revenue cliff once multiple generics hit?
Vafseo Q1 Visibility
Is the $4.5-$5 million channel inventory drain at USRC completely finished as of December 31, or is there residual inventory headwind bleeding into Q1 2026 that will obscure underlying patient demand for another quarter?